Notes:
The results of the three AF trials that directly compared aspirin to placebo are summarized. Although the AF trials all have wide confidence intervals, in aggregate they suggest an approximately 20% to 25% stroke risk reduction attributable to aspirin with no clear relationship to aspirin dose.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.